Skip to main content

Table 1 Clinical and Pathologic Features of Patients

From: Synuclein-γ (SNCG) expression in ovarian cancer is associated with high-risk clinicopathologic disease

Variable

N (%)

No. of patients

357

Follow up time, months

 Median

36

 Range

0–179

Age, year

 Median

63

 Range

22–93

CA125 level

  ≤ 485

141 (53.2)

  > 485

124 (46.8)

Ascites

 No

73 (29.1)

 Present

178 (70.9)

Optimal Debulking Surgery

 Optimal

245 (82.5)

 Suboptimal

52 (17.5)

Stage

 I

33 (9.8)

 II

31 (9.2)

 III

234 (69.2)

 IV

40 (11.8)

Primary Site of Disease

 Ovarian

300 (84.5)

 Primary Peritoneal

53 (14.9)

 Fallopian Tube

2 (0.6)

Histologic subtype

 Serous

262 (73.6)

 Clear cell

22 (6.2)

 Mucinous

12 (3.4)

Endometrioid

25 (7.0)

 Other

35 (9.8)

Grade (FIGO)

 1

7 (2.6)

 2

16 (6.1)

 3

240 (91.3)

Recurrence

 No

64 (32.8)

 Yes

131 (67.2)

SNCG Immunoexpression

 Negative

100 (28)

 Positive

257 (72)

Status

 Alive, No evidence of disease (ANED)

67 (18.8)

 Alive, with evidence of disease (AWED)

22 (6.2)

 Died of Disease (DOD)

268 (75.0)

Survival Time (months)

 Median

39

 95 % CI

34–44

Progression-free survival (months)

 Median

18

 95 % CI

15–23

  1. Some clinical information were missing from cases and thus the sum of cases for each feature listed may not equate to 357